-
Je něco špatně v tomto záznamu ?
The Role of Oncogenic Tyrosine Kinase NPM-ALK in Genomic Instability
C. Lobello, V. Bikos, A. Janikova, S. Pospisilova,
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články, přehledy
NLK
Free Medical Journals
od 2009
PubMed Central
od 2009
Europe PubMed Central
od 2009
ProQuest Central
od 2009-01-01
Open Access Digital Library
od 2009-01-01
Open Access Digital Library
od 2009-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2009
PubMed
29510549
DOI
10.3390/cancers10030064
Knihovny.cz E-zdroje
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Genomic stability is crucial for cell life and transmitting genetic material is one of the primary tasks of the cell. The cell needs to be able to recognize any possible error and quickly repair it, and thus, cells have developed several mechanisms to detect DNA damage and promote repair during evolution. The DNA damage response (DDR) and DNA repair pathways ensure the control of possible errors that could impair the duplication of genetic information and introduce variants in the DNA. Endogenous and exogenous factors compromise genomic stability and cause dysregulation in the DDR and DNA repair pathways. Cancer cells often impair these mechanisms to overcome cellular barriers (cellular senescence and/or apoptosis), leading to malignancy. NPM (nucleophosmin)-ALK (anaplastic lymphoma kinase) is an oncogenic tyrosine kinase that is involved in the development of anaplastic large cell lymphoma (ALCL). NPM-ALK is known to be involved in the activation of proliferative and anti-apoptotic signaling pathways. New evidence reveals that NPM-ALK translocation also impairs the ability of cells to maintain the genomic stability through both DDR and DNA repair pathways. This review aims to highlight the role of the oncogenic tyrosine kinase NPM-ALK in the cell, and pointing to new possible therapeutic strategies.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18009959
- 003
- CZ-PrNML
- 005
- 20190114091325.0
- 007
- ta
- 008
- 180404s2018 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/cancers10030064 $2 doi
- 035 __
- $a (PubMed)29510549
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Lobello, Cosimo $u Central European Institute of Technology (CEITEC), Masaryk University, Kamenice 5, 62500 Brno, Czech Republic. cosimo.lobello@ceitec.muni.cz.
- 245 14
- $a The Role of Oncogenic Tyrosine Kinase NPM-ALK in Genomic Instability / $c C. Lobello, V. Bikos, A. Janikova, S. Pospisilova,
- 520 9_
- $a Genomic stability is crucial for cell life and transmitting genetic material is one of the primary tasks of the cell. The cell needs to be able to recognize any possible error and quickly repair it, and thus, cells have developed several mechanisms to detect DNA damage and promote repair during evolution. The DNA damage response (DDR) and DNA repair pathways ensure the control of possible errors that could impair the duplication of genetic information and introduce variants in the DNA. Endogenous and exogenous factors compromise genomic stability and cause dysregulation in the DDR and DNA repair pathways. Cancer cells often impair these mechanisms to overcome cellular barriers (cellular senescence and/or apoptosis), leading to malignancy. NPM (nucleophosmin)-ALK (anaplastic lymphoma kinase) is an oncogenic tyrosine kinase that is involved in the development of anaplastic large cell lymphoma (ALCL). NPM-ALK is known to be involved in the activation of proliferative and anti-apoptotic signaling pathways. New evidence reveals that NPM-ALK translocation also impairs the ability of cells to maintain the genomic stability through both DDR and DNA repair pathways. This review aims to highlight the role of the oncogenic tyrosine kinase NPM-ALK in the cell, and pointing to new possible therapeutic strategies.
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Bikos, Vasilis $7 xx0231091 $u Central European Institute of Technology (CEITEC), Masaryk University, Kamenice 5, 62500 Brno, Czech Republic. vasileios.bikos@ceitec.muni.cz.
- 700 1_
- $a Janikova, Andrea $u Department of Internal Medicine-Hematology and Oncology, University Hospital Brno, 62500 Brno, Czech Republic. janikova.andrea@fnbrno.cz.
- 700 1_
- $a Pospisilova, Sarka $u Central European Institute of Technology (CEITEC), Masaryk University, Kamenice 5, 62500 Brno, Czech Republic. sarka.pospisilova@ceitec.muni.cz. Department of Internal Medicine-Hematology and Oncology, University Hospital Brno, 62500 Brno, Czech Republic. sarka.pospisilova@ceitec.muni.cz.
- 773 0_
- $w MED00173178 $t Cancers $x 2072-6694 $g Roč. 10, č. 3 (2018)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29510549 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180404 $b ABA008
- 991 __
- $a 20190114091534 $b ABA008
- 999 __
- $a ind $b bmc $g 1287444 $s 1006771
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 10 $c 3 $e 20180305 $i 2072-6694 $m Cancers $n Cancers $x MED00173178
- LZP __
- $a Pubmed-20180404